Navigation Links
Starch Medical Launches New, Bioinert Surgical Hemostats
Date:12/2/2008

SAN JOSE, Calif., Dec. 2 /PRNewswire/ -- Starch Medical Inc, a San Jose, CA-based medical device manufacturer, announces the CE approval of its PerClot(TM) Polysaccharide Hemostatic System (PHS) and the StarFoam(TM) Absorbable Polysaccharide Hemostat. Introduction of PerClot(TM) PHS will commence this month in the European Union and other select international markets. The StarFoam(TM) Absorbable Polysaccharide Hemostat will launch during the 2nd quarter, 2009.

PerClot(TM) PHS is an absorbable, surgical hemostat composed of Absorbable Modified Polymers (AMP(TM)). AMP(TM) technology incorporates sophisticated, plant-based polymer modification processes that yield biocompatible, polysaccharide particles. There is no thrombin, collagen, or other human or animal components in AMP(TM) particles. A family of customized, single-use application instruments will enhance the delivery of AMP(TM) to the wound site for the control of capillary, venous and arterial bleeding in both open and minimally invasive surgical procedures.

The StarFoam(TM) Absorbable Polysaccharide Hemostat, also developed with AMP(TM) technology, is produced in a hemostatic foam (wafer) configuration. Application of StarFoam(TM) will feature a simple "press and release" technique.

David Lang, President of SMI, commented, "The clinical introduction of PerClot(TM) PHS and its proprietary, integrated AMP(TM) technology represents the next generation of polysaccharide hemostatic agents. The StarFoam(TM) product line will offer surgeons a choice of hemostatic formats for a range of surgical wounds. Compared to current polysaccharide based hemostats, PerClot(TM) PHS and StarFoam(TM) demonstrate superior hydrophilic action and enhanced adhesive strength. These performance features, coupled with custom delivery systems, have been favorably received in a diverse range of surgical applications in Europe, Asia and Latin America."

SMI is a privately-held medical device company engaged in the design, manufacture, marketing and licensing of breakthrough, hemostatic solutions. Starch Medical's proprietary, patent-pending technology platform (AMP(TM)), including powders, foams and films, will focus on the worldwide, multi-billion dollar biomaterial, hemostasis, and wound care marketplace. For additional information, distribution inquiries, and licensing options, visit http://www.starchmedical.com.


'/>"/>
SOURCE Starch Medical Inc
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. DuPont and Plantic Technologies Announce Starch-Based Bio Materials Collaboration
2. Therapure Biopharma Inc. Announces Manufacturing Agreement with Biomedical Frontiers Incorporated -- Contract will Support Phase II Trials for Thalassemia Treatment
3. New Radiation-Blocking Medical Garments Introduced at RSNA Meeting in Chicago : Demron-M Technology Provides Total Protection in a Lightweight, Durable, Flexible Fabric
4. Shasta Regional Medical Center Awarded Full Accreditation from the Joint Commission
5. Varian Medical Systems Introducing OncoView(TM) - an Oncology Specific Image Management and Storage Solution
6. BioMarin Announces the Planned Retirement of Dr. Emil Kakkis, Chief Medical Officer
7. VNUS Medical Technologies to Present at Piper Jaffray 20th Annual Healthcare Conference
8. Noninvasive Medical Technologies Helps Make Young Tennessee Womans Wishes Come True
9. Promising Clinical Data on Gen-Probes APTIMA(R) HPV Test Presented at Major European Medical Meeting
10. VisualSonics and Seno Medical Instruments Sign Exclusive Opto-Accoustic Licensing Agreement for Preclinical Research
11. US District Court Enters Final Judgment in Favor of Smith & Nephew; Permanent Injunction Prohibits Arthrex Inc. From Selling Infringing Medical Devices
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)...  Bayer today announced that a Phase III ... (regorafenib) tablets for the treatment of patients with ... endpoint of a statistically significant improvement in overall ... and safety of regorafenib in patients with HCC ... The safety and tolerability were generally consistent with ...
(Date:5/4/2016)... (PRWEB) , ... May 04, 2016 , ... ... recent innovations in biotechnology to help treat hormonal and stress related hair loss. ... has captured the hearts of key opinion leaders in the medical and salon ...
(Date:5/3/2016)... , ... May 03, 2016 , ... ... at Boston CEO 2016 on May 31st and June 1st at The Four ... for leading executives in the life sciences, offering exclusive access to key decision ...
(Date:5/3/2016)... 2016 - And Other Rising ... of Those Competitor Biologics  - Biosimilar Drug ... Prospects ,  Who are the most important ... are their sales potentials? Discover, in our updated survey, ... opportunities and revenue forecasting. Visiongain,s ...
Breaking Biology Technology:
(Date:4/26/2016)... DUBLIN , April 27, 2016 ... of the  "Global Multi-modal Biometrics Market 2016-2020"  report ... ) , The analysts forecast ... a CAGR of 15.49% during the period 2016-2020.  ... a number of sectors such as the healthcare, ...
(Date:4/14/2016)... 2016 BioCatch ™, the ... announced the appointment of Eyal Goldwerger as ... Goldwerger,s leadership appointment comes at a time of ... deployment of its platform at several of the world,s ... discerns unique cognitive and physiological factors, is a winner ...
(Date:3/29/2016)... , March 29, 2016 ... "Company") LegacyXChange "LEGX" and SelectaDNA/CSI Protect are pleased to ... ink used in a variety of writing instruments, ensuring ... of originally created collectibles from athletes on LegacyXChange will ... analysis of the DNA. Bill Bollander ...
Breaking Biology News(10 mins):